Aktienanalyse zu Neurosense Therapeutics Ltd (NRSN)NRSNNeurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Neurosense Therapeutics Ltd is currently not a strong buy due to its ongoing financial losses and compliance risks, despite some positive catalysts. The current price is $0.42, which is significantly below the analyst's target of $3, indicating potential upside. However, the company reported a net income loss of $2.15 million for Q3 2024, and it faces a Nasdaq compliance warning for trading below $1.00, which poses a risk to its listing status.